Results 201 to 210 of about 254,141 (317)

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

open access: yesArthritis &Rheumatology, EarlyView.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie   +8 more
wiley   +1 more source

Glucocorticoid therapy and adrenal suppression

open access: bronze, 2017
Damir Benc   +9 more
openalex   +2 more sources

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

Anti-Cancer Outcome of Glucocorticoid Receptor Transrepression by Synephrine Derivatives in Hematological Malignancies. [PDF]

open access: yesInt J Mol Sci
Zhidkova EM   +15 more
europepmc   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Late‐Onset Spondyloarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin ‐17 Blockade May Have a Therapeutic Role

open access: yesArthritis &Rheumatology, EarlyView.
Objective Polymyalgia rheumatica (PMR) is an age‐related inflammatory disease with shoulder/hip girdle involvement. Magnetic resonance imaging (MRI) reveals extracapsular/entheseal soft tissue involvement in both PMR and spondyloarthritis (SpA), with sacroiliac joint and perientheseal spinal bone marrow edema (BME) being characteristic of SpA ...
Kerem Abacar   +12 more
wiley   +1 more source

Can Vitamin D Reduce Glucocorticoid-Induced Adverse Effects in Patients with Giant Cell Arteritis? Results from 1568 Patients in the Spanish ARTESER Registry. [PDF]

open access: yesNutrients
Ghio GA   +21 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy